Fig. 1.

Identification of mebendazole as a promoter of c-Maf protein degradation. a The system for screening c-Maf/USP5 inhibitors. b HEK293T cells were plated in 96-well plates (10 000 cells per well) 24 h before being cotransfected with plasmids, including the c-Maf, USP5 and pMARE.Luci plasmids. On the third day, cells were treated with each compound from the drug library for 24 h before being lysed for luciferase assays. The activities of the compounds were expressed as log2 (sample luciferase RLU/control luciferase RLU). Drugs associated with a value of log2 < -1 were considered potential inhibitors. c, d LP1 cells were treated with candidate drugs at the indicated concentrations for 24 h, followed by IB assays and RT-PCR for the indicated proteins/genes